|
Volumn 17, Issue 13, 2007, Pages 3544-3549
|
Structure-activity relationships of SERMs optimized for uterine antagonism and ovarian safety
a a a a a a a a a a a a a a a a a a a b more.. |
Author keywords
Blood brain barrier; ER; Estrogen; Estrogen receptor; HPO axis; Hypothalamic pituitary ovarian axis; Leiomyomas; Selective estrogen receptor modulator; SERM; Uterine fibroids
|
Indexed keywords
4 HYDROXYTAMOXIFEN;
BENZOTHIOPHENE;
CLOMIFENE;
ESTROGEN;
ESTROGEN RECEPTOR;
ETHINYLESTRADIOL;
FOLLITROPIN;
GONADORELIN;
GONADORELIN AGONIST;
LUTEINIZING HORMONE;
NAPHTHALENE;
SELECTIVE ESTROGEN RECEPTOR MODULATOR;
TAMOXIFEN;
ANIMAL CELL;
ANIMAL EXPERIMENT;
ANIMAL MODEL;
ARTICLE;
CONTROLLED STUDY;
DISEASE MARKER;
DRUG ANTAGONISM;
DRUG EFFECT;
DRUG EFFICACY;
DRUG SAFETY;
ESTROGEN BLOOD LEVEL;
FEMALE;
HUMAN;
HUMAN CELL;
HYPOTHALAMUS HYPOPHYSIS SYSTEM;
IC 50;
NONHUMAN;
OSTEOLYSIS;
OVARY;
OVARY CYST;
RAT;
SIDE EFFECT;
STIMULATION;
STRUCTURE ACTIVITY RELATION;
UTERUS;
UTERUS MYOMA;
ANIMALS;
BRAIN;
DOSE-RESPONSE RELATIONSHIP, DRUG;
DRUG DESIGN;
ESTROGENS;
FEMALE;
HUMANS;
LEIOMYOMA;
MODELS, CHEMICAL;
OVARY;
RATS;
RATS, SPRAGUE-DAWLEY;
SELECTIVE ESTROGEN RECEPTOR MODULATORS;
SOFTWARE;
STRUCTURE-ACTIVITY RELATIONSHIP;
|
EID: 34250173512
PISSN: 0960894X
EISSN: None
Source Type: Journal
DOI: 10.1016/j.bmcl.2007.04.044 Document Type: Article |
Times cited : (12)
|
References (21)
|